Skip to main content
Log in

Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

SCH 39166 is the first selective D1 dopamine receptor antagonist developed for the treatment of schizophrenic patients. To examine potential antipsychotic effect, tolerability and safety, SCH 39166 was given orally to 17 acutely ill drug free schizophrenic patients (DSMIIIR) in an open 4-week study. Doses were escalated from 10 to 100 mg b.i.d. according to a fixed schedule over 17 days and remained at 100 mg b.i.d. for another 11 days. The drug was withdrawn prematurely in ten patients because of deterioration or refusal to take SCH 39166. In the nine patients participating for more than 2 weeks, none had an apparent reduction of BPRS or CGI scores. Side effects were agitation, akathisia and emesis in single patients. After withdrawal of SCH 39166 of the patients improved when treated with classical neuroleptics or clozapine. The result of the study does not support the prediction that selective D1 dopamine receptor antagonism will produce antipsychotic effects in schizophrenia

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676

    Google Scholar 

  • Bishop MP, Gallant DM (1966) Observations of placebo response in chronic schizophrenic patients. Arch Gen Psychiatry 14:497–503

    Google Scholar 

  • Braude WM, Barnes TRE, Gore SM (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric in patient admission. Br J Psychiatry 143:139–150

    Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Google Scholar 

  • Chipkin RD, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphtazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102

    Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multi-center placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40

    Google Scholar 

  • Clark D, White FJ (1987) Review: D1 dopamine receptor — the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1:347–388

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • Daly SA, Waddington JL (1991) Two directions of dopamine D1/D2 receptor interactions in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur J Pharmacol 213:251–258

    Google Scholar 

  • Delini-Stula A, Berdah-Tordjman D (1994) Placebo controlled studies in acute schizophrenia — an issue of concern. Eur Psychiatry 9:165–173

    Google Scholar 

  • Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258–261

    Google Scholar 

  • Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using11C-SCH 23390 and11C-raclopride. Psychopharmacology 92:278–284

    Google Scholar 

  • Farde L, Wiesel F-A, Halldin C, Sedvall G (1988a) Central D2-dopamine occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Google Scholar 

  • Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988b) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94:1–7

    Google Scholar 

  • Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) PET-analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine — relation to extrapyramidal side effect. Arch Gen Psychiatry 49:548–544

    Google Scholar 

  • Farde L, Nordström A-L, Nyberg S, Halldin C, Sedvall G (1994) D1-, D2- and %-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55:67–69

    Google Scholar 

  • Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F-A, Wik G, Åberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients — a double-blind comparison with chlorpromazine. Acta Psychiatr Scand [Suppl] 311 [69]:7–30

    Google Scholar 

  • Härnryd C, Bjerkenstedt L, Gullberg B (1989) A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward. Acta Psychiatr Scand [Suppl] 352 [80]:40–47

    Google Scholar 

  • Imperato A, Obino MC, Casu MA, Mascia MS, Dazzi L, Gessa GL (1993) Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. J Pharmacol Exp Ther 266:557–562

    Google Scholar 

  • Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. Pharmacol Exp Ther 226:462–468

    Google Scholar 

  • Johnstone EC, Crow TJ, Frith CD, Carney MWP (1978) Mechanisms of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 22:848–851

    Google Scholar 

  • Kane JM, Mardner SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287–302

    Google Scholar 

  • Karlsson P, Farde F, Halldin C, Swahn C-G, Sedvall G (1995a) Evaluation of SCH 39166 as a PET ligand for D1-dopamine receptor binding and occupancy in healthy men. Psychopharmacology 121:300–308

    Google Scholar 

  • Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, Sloth-Nielsen M (1995b) Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology 119:1–8

    Google Scholar 

  • Lindstrom E, Wieselgren I-M, Von Knoring L (1993) Interrater reliability of the structured clinical interview for the positive and negative syndrome scale for schizophrenia. Acta Psychiatr Scand 89:192–195

    Google Scholar 

  • McHugh D, Coffin V (1991) The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist. Eur J Pharmacol 202:133–134

    Google Scholar 

  • McQuade RD, Duffy RA, Anderson CC, Crosby G, Coffin VL, Chipkin RE, Barnett A (1991) [3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses. J Neurochem 57:2001–2010

    Google Scholar 

  • Mitchelson F (1992) Pharmacological agents affecting emesis. A review (Part I). Drugs 43:295–315

    Google Scholar 

  • Nielsen EB, Andersen PH (1992) Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol 219:35–44

    Google Scholar 

  • Nybäck H, Sedvall G (1968) Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J Pharmacol Exp Ther 162:294–301

    Google Scholar 

  • Saller CF, Salama AI (1986) D1-Dopamine receptor stimulation elevates plasma prolactin levels. Eur J Pharmacol 122:139–142

    Google Scholar 

  • Sedvall G, Farde L, Persson A, Wiesel F-A (1986a) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43:995–1005

    Google Scholar 

  • Sedvall G, Farde L, Stone-Elander S, Halldin C (1986b) Dopamine D1-receptor binding in the living human brain. In: Breese GR, Creese I (eds) Neurobiology of central D1-dopamine receptors. Plenum, New York, pp 119–124

    Google Scholar 

  • Sedvall G, Farde L, Barnett A, Hall H, Halldin C (1991)11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacology 103:150–153

    Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic-dopamine receptors. Nature 261:717–719

    Google Scholar 

  • Setler PE, Sarau HM, Zirkle CL, Sauders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430

    Google Scholar 

  • Sibley DR, Monsma FJJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69

    Google Scholar 

  • Van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492–494

    Google Scholar 

  • Waddington JL, Daly SA, McCauley PG, O'Boyle KM (1994) Levels of functional interaction between D1-like and D2-like dopamine receptor systems. In: Niznik HB (eds) Dopamine receptors and transporters. Marcel Dekker, New York, pp 511–537

    Google Scholar 

  • Wiesel F-A, Nordström A-L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 14:31–38

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karlsson, P., Farde, L., Härnryd, C. et al. Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121, 309–316 (1995). https://doi.org/10.1007/BF02246068

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246068

Key words

Navigation